This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Inotrem. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Kevin Carrasco: Innovator in Septic Shock Treatment
Introduction
Kevin Carrasco, an innovative inventor hailing from Dombasle-sur-Meurthe, France, is making significant strides in medical treatments. He is known for his groundbreaking patent, which focuses on a method for treating septic shock. With one patent to his name, Carrasco has showcased his dedication to addressing acute inflammatory disorders.
Latest Patents
Carrasco's key patent is titled "Method for treating septic shock." This patent outlines a method that involves administering a TREM-1 inhibitor to subjects exhibiting elevated soluble TREM-1 (sTREM-1) levels in their biological samples. By specifically targeting individuals with sTREM-1 levels exceeding a predetermined value, his method aims to effectively treat septic shock, an acute and potentially life-threatening condition.
Career Highlights
Carrasco is currently associated with Inotrem, a company dedicated to advancing treatments for severe inflammatory conditions. His work there emphasizes the importance of innovative strategies in medical science, aligning with the company’s mission to develop therapies that improve patient outcomes.
Collaborations
In his professional journey, Carrasco collaborates with talented individuals, including his coworker, Aurelie Olivier. Their combined expertise enhances the research and development efforts at Inotrem, facilitating breakthroughs in treating critical health conditions.
Conclusion
Kevin Carrasco stands out as a pivotal figure in the realm of medical innovation, particularly in the treatment of septic shock. His patented method not only underscores his commitment to advancing healthcare but also reflects the potential for improving the lives of countless individuals affected by severe inflammatory disorders. As he continues to work at Inotrem alongside skilled colleagues, the future appears promising for further innovative contributions to medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile